R&D nke Sorrento lekwasịrị anya na ịnya ụgbọ ala ọhụrụ na COVID-19, ọgwụgwọ ọrịa kansa, njikwa mgbu zuru oke na ọrịa autoimmune.

Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Mmemme COVID-19
COVISTIX™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ikike iji ihe mberede (EUA) na Mexico (COFEPRIS), Brazil (ANVISA), na CE akara na Europe. COVIMARK™ (nchọpụta nchọpụta) Nnwale Antigen ngwa ngwa 0%* Ngwa etinyere na US na Canada maka ikike iji ihe mberede (EUA) COVISHIELD™ (ọgwụgwọ) Antibody na-anọpụ iche (IN) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ 40%* COVISHIELD™ (ọgwụgwọ) Neutralizing Antibody (IV) n'ime ndị ọrịa na-arịa ọrịa na ndị ọrịa nọ n'ụlọ ọgwụ 20%* FUJOVEE (Abivertinib) COVID-19 siri ike na ndị ọrịa ICU 82%* Ọnwụnwa dị mkpa na-echere mkpochapụ FDA OQORY™ (COVI-MSC) ARDS n'ihi COVID-19 n'ime ndị ọrịa ICU 82%* Ọnwụnwa dị mkpa na Brazil Mpro Ihe mgbochi (ọgwụ ọnụ) Ọrịa mgbochi 40%* Omicron mRNA ogwu Vaccine 20%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
immunotherapy
FUJOVEE (Abivertinib) NSCLC 82%* FUJOVEE (Abivertinib) B cell Lymphomas 60.2%* FUJOVEE (Abivertinib) Prostate 20%* FUJOVEE (Abivertinib) Lupus 20%* FUJOVEE (Abivertinib) MS 20%* FUJOVEE (Abivertinib) GvHD 20%* PD-L1 (Socazolimab)* SCLC 82%* * Na mmekorita ya na Lee's Pharm na China PD-L1 (STI-3031)** Ọrịa Cervical 82%* ** Na US yana mmekorita ya na ImmuneOncia na Korea CD47 Tumor siri ike 40%* CD38 DAR-T multiple Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, na esophageal 40%* TROP2 ADC* Tumor siri ike 40%* * Na China Seprehvec™ oncolytic nje Tumor siri ike; CNS Tumor 40%* Ọnụ ego nke BCMA ADC Tumor Liquid 20%* Bevacizumab-ADNAB™ Ọrịa kansa Endometrial 40%* Na mmekorita ya na Mayo Clinic Bevacizumab-ADNAB™ Ọrịa Ovarian 40%* Na mmekorita ya na Mayo Clinic Rituximab-ADNAB™ B-cell Lymphomas 40%* Na mmekorita ya na Mayo Clinic
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Pain
ZTlido™ 1.8% Neuralgia Postherpetic - PHN 99.8%* SP-102 (SEMDEXA) Lumbar Radicular/Sciatica mgbu 82%* SP-103 (Sistemụ Topical Lidocaine 5.4%) Nnukwu Mgbu mgbu 20%* SP-104 (Naltrexone obere dose gbawara egbu oge) Fibromyalgia 20%* RTX (resiferatoxin) Epidural injection Ihe mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu 60.3%* Nhọpụta nwa mgbei RTX (resiferatoxin) Ụzọ intra-articular OA Mgbu OA Na-agafeghị agafe ruo Dị Ike 60.2%*
Mmemme igodo	Ntu	Mgbochi	Na-adọ 1	Oge Abụọ	Nkeji III/Pivotal	Nkwado FDA
Nnyefe Lymphatic
Sofusa® mgbochi TNF Autoimmune (RA) 40%* Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL) 40%* Sofusa® mgbochi CTLA-4 Melanoma 40%* Na mmekorita ya na Mayo Clinic

Mmemme COVID-19
Mmemme igodo (Ngosipụta)	adọ
COVISTIX™ (nchọpụta nchọpụta) FDA EUA COVIMARK™ (nchọpụta nchọpụta) FDA EUA COVISHIELD™ (ọgwụgwọ) PH I COVISHIELD™ (ọgwụgwọ) Mgbochi FUJOVEE (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III Mpro Inhibitor (mkpụrụ ọgwụ ọnụ) (mgbochi nje) Ph I Omicron mRNA ogwu (ọgwụ mgbochi) Mgbochi

immunotherapy
Mmemme igodo (Ngosipụta)	adọ
FUJOVEE™ (Abivertinib) (NSCLC) Ph III FUJOVEE™ (Abivertinib) Lymphoma nke mkpụrụ ndụ B cell Ph II FUJOVEE™ (Abivertinib) (Prostate) Mgbochi FUJOVEE™ (Abivertinib) (Lupus) Mgbochi FUJOVEE™ (Abivertinib) (MS) Mgbochi FUJOVEE™ (Abivertinib) (GvHD) Mgbochi PD-L1 (Socazolimab)*(SCLC) Ph III PD-L1 (STI-3031)** (Cervical Cancer) Ph III CD47 Tumor siri ike Ph I CD38 DAR-T (Otu Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, na esophageal) Ph I TROP2 ADC* Tumor siri ike Ph I Seprehvec™ oncolytic nje Tumor siri ike (CNS Tumors) PH I Ọnụ ego nke BCMA ADC ( Tumor Liquid) Mgbochi Bevacizumab-ADNAB™ (ọrịa cancer endometrial) Ph I Bevacizumab-ADNAB™ (ọrịa cancer ovarian) Ph I Rituximab-ADNAB™ (B-cell Lymphomas) Ph I

Pain
Mmemme igodo (Ngosipụta)	adọ
ZTlido™ 1.8% (Postherpetic Neuralgia - PHN) Nkwado FDA SP-102 (SEMDEXA) Ph III SP-103 (Sistemụ Topical Lidocaine 5.4%) Mgbochi SP-104 (Naltrexone obere dose gbawara egbu oge) Mgbochi RTX (resiniferatoxin) ogwu ogwu ogwu (Mgbu na-adịghị agwụ agwụ na ọrịa kansa dị elu) Ph II RTX (resiniferatoxin) Ụzọ intra-articular (Ọ dị oke oke ruo nke ukwuu mgbu ikpere OA) Ph II

Nnyefe Lymphatic
Mmemme igodo (Ngosipụta)	Oge Abụọ
Sofusa® mgbochi TNF (Akụkụ nke onwe RA) Ph I Sofusa® mgbochi PD-1 Ọrịa T-cell Lymphoma (CTCL) Ph I Sofusa® mgbochi CTLA-4 (Melanoma) Ph I